ZLY06

ZLY06 is an orally active dual agonist of peroxisome proliferator-activated receptor (PPAR) δ and γ (PPAR δ: EC50=341 nM; PPAR γ: EC50=237 nM) . ZLY06 induces hepatic lipid accumulation by inhibiting the phosphorylation of AKT1, mediating the upregulation of CD36. In addition, ZLY06 significantly improves glucose and lipid metabolism without increasing body weight, and alleviates fatty liver by promoting β-oxidation of fatty acids and inhibiting hepatic lipogenesis[1][2].

Product Specifications

CAS Number

[2834727-04-5]

UNSPSC

12352005

Target

Akt; PPAR

Type

Reference compound

Related Pathways

Cell Cycle/DNA Damage; Metabolic Enzyme/Protease; PI3K/Akt/mTOR; Vitamin D Related/Nuclear Receptor

Field of Research

Metabolic Disease

Assay Protocol

https://www.medchemexpress.com/zly06.html

Concentration

10mM

Purity

98.75

Solubility

DMSO : 100 mg/mL (ultrasonic)

Smiles

CC1=CC(/C=C2OC(C=C(OCC3CC3)C=C4)=C4C\2=O)=CC(C)=C1OC(C)(C)C(O)=O

Molecular Formula

C25H26O6

Molecular Weight

422.47

References & Citations

[1]Zheng Li, et al. "Discovery of the first-in-class dual PPARδ/γ partial agonist for the treatment of metabolic syndrome." European Journal of Medicinal Chemistry 225 (2021) : 113807.|[2]Xiaotong Cai, et al. "Novel Dual PPAR δ/γ Partial Agonist Induces Hepatic Lipid Accumulation through Direct Binding and Inhibition of AKT1 Phosphorylation, Mediating CD36 Upregulation." Chemical Research in Toxicology (2024) .